Pascal Biosciences and Y-Biologics Announce Research Collaboration for Development of a Bispecific Antibody for Leukemia

In a news release, Pascal Biosciences Inc. and Y-Biologicstoday announced a research collaboration agreement for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Under the terms of the agreement, Y-Biologics will contribute its novel bispecific antibody platform technology, ALiCE, and Pascal will utilize its proprietary antibodies. The Companies will share responsibility for the discovery and validation of lead candidates and pursuing the optimal development path. Further terms were not disclosed. 

“We are excited by the opportunity to advance our novel antibodies with the leading bispecific antibody technology developed by Y-Biologics,” said Patrick Gray, Ph.D., CEO of Pascal. “This agreement allows us both to collaborate in the advancement of ground-breaking technology for treating leukemia.”

“We are delighted that Pascal has recognized the potential of our proprietary bispecific antibody platform technology, ALiCE, to address unmet medical needs in leukemia. Pascal is a desirable partner for Y-Biologics with their expertise in oncology and commitment to develop novel therapeutics, and we are confident that our collaboration will provide new clinical options for leukemia patients,” said Young-Woo Park, Ph.D., CEO of Y-Biologics.